Topiramate in the treatment of obese subjects with drug‐naive type 2 diabetes
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Aim: The aim of this study was to examine the efficacy and safety of topiramate as an adjunct to diet and exercise in drug‐naive, obese subjects with type 2 diabetes. Methods: Drug‐naive individuals with type 2 diabetes, body mass index (BMI) of ≥27 and <50 kg/m 2 and haemoglobin A 1c (HbA 1c ) of <10.5% were enrolled into the study. All the individuals participated in a non‐pharmacologic weight loss program (Pathways to Change ® ; Johnson & Johnson Healthcare Systems, Piscataway, NJ, USA) throughout the trial. After a 6‐week placebo run‐in, the subjects were randomized to placebo, topiramate 96 mg/day or topiramate 192 mg/day. Subjects were scheduled for 8‐week titration and 52‐week maintenance phases. The study was ended early; efficacy data were reported for a predefined modified intent‐to‐treat (MITT) population (n = 229), with 40 weeks of treatment. All the subjects who provided any safety data were included in the safety population (n = 535). Results: Baseline mean weight was 103.7 kg, BMI 36 kg/m 2 and HbA 1c 6.7% across all treatment groups. By the end of week 40, the placebo, the topiramate 96 mg/day and topiramate 192 mg/day groups lost 2.5, 6.6 and 9.1% of their baseline body weight respectively (p < 0.001 vs. placebo, MITT population using last observation carried forward). The decrease in HbA 1c was 0.2, 0.6 and 0.7% respectively (p < 0.001 vs. placebo, MITT). Topiramate significantly reduced blood pressure and urinary albumin excretion; a weight‐loss‐independent HbA 1c improving effect of topiramate was demonstrated. Adverse events were predominantly related to central nervous system (CNS). Conclusions: Topiramate as an add‐on treatment to lifestyle improvements produced significant weight loss and improved glucose homeostasis in obese, drug‐naive subjects with type 2 diabetes. These treatment advantages should be balanced against the occurrence of adverse events in the CNS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035622 · Cited by 4,457
Self-citationDiet, lifestyle, and the risk of type 2 diabetes mellitus in women.
Hu, F. B., Manson, J. E., Stampfer, M. J., Colditz, G., Liu, S., Solomon, C. G., & Willett, W. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010492 · Cited by 2,901
Weight gain as a risk factor for clinical diabetes mellitus in women
Colditz, G. A., Willett, W. C., Rotnitzky, A., & Manson, J. E. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-7-199504010-00001 · Cited by 2,064
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Obesity, Fat Distribution, and Weight Gain as Risk Factors for Clinical Diabetes in Men
Chan, J. M., Rimm, E. B., Colditz, G. A., Stampfer, M. J., & Willett, W. C. (1994) · Diabetes Care · doi:10.2337/diacare.17.9.961 · Cited by 1,808
Oral topiramate for treatment of alcohol dependence: A randomised controlled trial
Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Javors, M. A., & Ma, J. Z. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13370-3 · Cited by 743
Achieving Weight and Activity Goals Among Diabetes Prevention Program Lifestyle Participants
The Diabetes Prevention Program Research Group (2004) · Obesity Research · doi:10.1038/oby.2004.179 · Cited by 529
Bray, G. A., Hollander, P., Klein, S., Kushner, R., Levy, B., Fitchet, M., & Perry, B. H. (2003) · Obesity Research · doi:10.1038/oby.2003.102 · Cited by 344
Self-citationfor the OBES-002 Study Group, Wilding, J., Gaal, L. V., Rissanen, A., Vercruysse, F., & Fitchet, M. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802783 · Cited by 224
Self-citationType ii diabetic subjects lose less weight than their overweight nondiabetic spouses
Wing, R. R., Marcus, M. D., Epstein, L. H., & Salata, R. (1987) · Diabetes Care · doi:10.2337/diacare.10.5.563 · Cited by 190
Topiramate: Long‐Term Maintenance of Weight Loss Induced by a Low‐Calorie Diet in Obese Subjects
Astrup, A., Caterson, I., Zelissen, P., Guy‐Grand, B., Carruba, M., Levy, B., Sun, X., Fitchet, M., & OBES‐004 Study Group (2004) · Obesity Research · doi:10.1038/oby.2004.206 · Cited by 143
Self-citationWilliamson, D. F. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1212031 · Cited by 32
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease
Dudley, J. T., Sirota, M., Shenoy, M., Pai, R. K., Roedder, S., Chiang, A. P., Morgan, A. A., Sarwal, M. M., Pasricha, P. J., & Butte, A. J. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002648 · Cited by 605
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
Grunvald, E., Shah, R., Hernaez, R., Chandar, A. K., Pickett-Blakely, O., Teigen, L. M., Harindhanavudhi, T., Sultan, S., Singh, S., & Davitkov, P. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.08.045 · Cited by 347
Efficacy and safety of topiramate on weight loss: a meta‐analysis of randomized controlled trials
Kramer, C. K., Leitão, C. B., Pinto, L. C., Canani, L. H., Azevedo, M. J., & Gross, J. L. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00846.x · Cited by 323
Metadata
- Authors
- Stenlöf, K., Rössner, S., Vercruysse, F., Kumar, A., Fitchet, M., Sjöström, L., & Study Group
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2006-08-04
- Volume
- 9
- Issue
- 3
- Pages
- 360-368
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1967462033
- Cited by
- 77
- References
- 12
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.